{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.0"},{"groupId":"OG001","value":"80.0"}]}],"title":"Absent (72 hours post dose) (n=61, 35)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0"},{"groupId":"OG001","value":"20.0"}]}],"title":"Present (72 hours post dose) (n=61, 35)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.5"},{"groupId":"OG001","value":"94.4"}]}],"title":"Absent (7 days post dose) (n=67, 36)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5"},{"groupId":"OG001","value":"5.6"}]}],"title":"Present (7 days post dose) (n=67, 36)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"The study physician assessed the most affected joint for Erythema: Present or absent. The percentage of patients in each category is reported. The treatment effect reported for canakinumab arm was for last post-baseline flare after re-treated with canakinumab and for patient which switched to Canakinumab arm was for first post-baseline flare after receiving the first dose of canakinumab.","groups":[{"description":"Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.\n\nAfter completing the first extension study, patients were offered to enter the second extension study, whereby all patients were treated open-label \"on demand\" with canakinumab 150 mg sc upon new flare for 1 year for a total duration of 18 months following randomization in the core study.","id":"OG000","title":"Randomized to Canakinumab and Re-treated With Canakinumab"},{"description":"Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 week extension study for any new gout flare on demand with the same treatment as assigned in the core study.\n\nPatients under this arm who agreed to continue to 2nd extension period of 12 months, were switched to canakinumab 150 mg sc for any new gout flare during this period","id":"OG001","title":"Randomized to Triamcinolone and Switched to Canakinumab"}],"paramType":"NUMBER","populationDescription":"Modified Analysis Set (MAS) consists of all FAS patients who were either re-treated or switched to canakinumab during 72 weeks. At each timepoint only patients with a value at both baseline flare and the new flare are included.","reportingStatus":"POSTED","timeFrame":"72 hours post-dose , 7 days post dose for the last post-baseline flare for patients re-treated with canakinumab or the first post-baseline flare treated with canakinumab for patients who switched treatment (during 72 weeks overall)","title":"Physician's Assessment of Erythema for Patients Re-treated or Switched to Canakinumab","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}